Dr. Paresh Sharma received his PhD (2010) from BITS Pilani, India. He did his Post-doctoral work in Malaria Biology at the NIAID, National Institute of Health (NIH), USA from 2010-2013. He joined the National Institute of Animal Biotechnology in 2013.

Dr. Paresh’s has extensive research experience in the field of Microbiology, Cell Biology, Immunology and Genomics. His research interest has been focused on understanding the molecular mechanisms behind major intracellular parasitic diseases for identifying new drug treatments, diagnostic tools, and vaccines. During his PhD and Postdoctoral work he has used genetic and genomic approaches to study the host parasite interaction and molecular mechanisms using the protozoan parasites Plasmodium falciparum, Leishmania donovani and Trypanosma brucei as a model.

Google Scholar Link:

https://scholar.google.co.in/citations?user=2tTBQ5MAAAAJ&hl=en

Research Focus

Welcome to the Host-Microbe Interactions and Epigenetics Laboratory

At the National Institute of Animal Biotechnology (NIAB), our laboratory is dedicated to deciphering the dynamic interplay between pathogens and their hosts. We employ cutting-edge genomic, epigenomic, and proteomic approaches to unravel the molecular foundations of infectious diseases, with the ultimate goal of developing innovative strategies for disease control.

Our Core Research Themes
1. Hemoprotozoan Parasites: Unraveling Complexity
     We focus on understanding the pathogenesis of economically significant haemoprotozoan parasites. Our research encompasses:

• Genomic Surveillance:Tracking parasite evolution and diversity in the field.
• Drug Discovery & Repurposing:Identifying new uses for existing drugs to fast-track treatment options.
• Mechanisms of Pathogenesis:Investigating how these parasites cause disease, with a special emphasis on:
• Host-Parasite Interactions:Using epigenetics and proteomics to understand how parasites manipulate host cells.
• Post-Translational Modifications (PTMs):Studying how PTMs regulate protein function in both the host and the pathogen during infection.
  
  2. Antimicrobial Resistance (AMR): Confronting the ESKAPE Pathogens
      We are tackling the global threat of AMR in bacterial pathogens, particularly the critical ESKAPE group. Our efforts include:
• Genomic Surveillance of AMR:Monitoring the spread and emergence of resistance genes.
• Deciphering Resistance Mechanisms:Uncovering the molecular pathways bacteria use to evade antibiotics.

Novel Antimicrobial Discovery:Tapping into the untapped potential of the gut microbiome, a gold mine for bioactive metabolites, to identify new antimicrobial compounds.

Our Mission
By integrating fundamental discovery with translational science, we aim to transform our findings into practical solutions, novel drugs, vaccines, and diagnostics that enhance animal health, ensure food security, and contribute to sustainable agriculture both nationally and internationally.

Bovine Theileriosis: Deciphering a Parasite-Induced Cancer

Theileria annulata is a master of cellular hijacking. This intracellular parasite doesn’t just infect bovine white blood cells; it transforms them. Infected cells lose control over their growth, become immortalized, and spread throughout the host’s body in a process that mirrors cancer metastasis.

Our lab is at the forefront of investigating this remarkable phenomenon. We seek to unravel the molecular toolkit T. annulata uses to reprogram its host, effectively creating a parasite-driven “cancer.” By understanding these mechanisms, we are uncovering fundamental principles of both infectious disease and cellular transformation.

Our Approach:
We employ cutting-edge integrative multi-omics combining genomics, epigenomics, and proteomics to answer key questions:

• How does the parasite manipulate host cell signaling and survival pathways?
• What are the key epigenetic “switches” that lock the cell in a proliferative state?
• How does parasite diversity influence the virulence and transformation potential?

From Insight to Intervention:
Our research is translationally driven. We are leveraging our discoveries to develop tangible solutions for farmers:

• Identifying Novel Targets:Finding parasite-specific pathways for new drugs or vaccines.
• Drug Repurposing:Fast-tracking existing oncology or antimicrobial drugs for Theileriosis treatment.
• Advanced Diagnostics:Creating rapid, accurate tools for early detection in the field.

By targeting the unique biology of this cancer-like parasite, our work aims to mitigate significant economic losses in the livestock sector and pioneer new strategies for sustainable animal health.

Theileria annulata Hijacks Host Signaling: Integrated Phosphoproteomics and Transcriptomics Unveils ERK1/2 as a Central Regulator of Host Transcription Factors
Theileria-transformed bovine leukocytes exhibit cancer-like characteristics, but the molecular mechanisms driving these transformations remain unclear. This study provides the first comprehensive phosphoproteomic analysis of both host and parasite in T. annulata–infected leukocyte cell lines. We show that T. annulata significantly induces changes in the host protein phosphorylation, impacting key cancer-related processes such as apoptosis suppression, CAMK signaling, and telomere maintenance. A pivotal finding is the parasite’s manipulation of the MAPK pathway via sustained ERK1/2 activation, which regulates the phosphorylation of critical transcription factors like RUNX3, FOSL2, BCL6, c-JUN, JUNB, and c-MYC. Transcriptomic analysis of genes controlled by these transcription factors confirmed their role in T. annulata replication. ERK inhibition disrupts phosphorylation, deactivates these transcription factors, and induces apoptosis in infected cells. This underscores the ERK-AP-1 axis as a central mechanism of Theileria pathogenesis and a promising therapeutic target. Additionally, parasite-specific phosphoproteins and kinases were identified, offering new insights into therapeutic strategies to combat infection.

Genomic characterization of host gene alterations in Theileria annulata-transformed leukocytes
T. annulata-infected host leukocytes exhibit cancer-like phenotypes, driven by mechanisms that remain incompletely understood. This study explores the genomic alterations underlying these transformations using whole-genome sequencing and bioinformatic analyses of six clinically relevant T. annulata-infected cell lines. Here we identify 7,867 exon-linked somatic mutations shared across all cell lines, with significant enrichment in oncogenes (e.g., FLT4, NOTCH2, MAP3K1, DAXX, FCGR2B, ROS1) and tumor suppressor genes (e.g., BARD1, KMT2C, GRIN2A, BAP1). These mutations are associated with critical cancer-related pathways. Functional studies revealed that inhibition of the mutated oncogene ROS1 using crizotinib induces death in infected leukocytes, confirming its role in transformation. Additionally, we observe mutations in genes linked to genomic instability and the DNA damage response (DDR) pathways, highlighting potential parallels with cancer biology. Suppression of TP53, a key tumor suppressor, is implicated in the immortalization of infected cells, while upregulation of the DNA mutator enzyme APOBEC3H suggests a parasite-driven, mutation-inducing mechanism. Our findings provide new insights into how T. annulata reprograms host cells through genomic instability and mutations, identifying ROS1 and TP53 as critical targets for therapeutic intervention. This work advances understanding of parasite-induced oncogenic transformation and offers pathways for future research.

Epigenetic Reprogramming of Host Chromatin by the Transforming Parasite Theileria annulata
T. annulata, a transforming apicomplexan parasite, extensively reprograms the chromatin architecture of bovine leukocytes to facilitate infection and cellular transformation. To elucidate the underlying epigenetic mechanisms, we characterized the chromatin landscape of infected lymphocytes using integrated proteomic, imaging, and functional assays. Our findings reveal that T. annulatalacks the DNA damage marker γH2A.X and its associated SQ/TQ motif, indicating an evolutionary divergence from canonical DNA repair signalling pathways.
High-resolution profiling of histone post-translational modifications (PTMs) demonstrated distinct nuclear compartmentalization, with host (H3K27me3, H3K9me1/2), parasite-predominant modifications (H3K4me3, H3K18me1, H3K27ac, H3K9ac, and H3K36me3), and shared modifications (e.g., H3K4me1/2, H3K36me2, H4K5/8/12/16ac, H3K9me3 and H4K91Ac) suggesting a coordinated epigenetic strategy driving host cell programs to sustain proliferation and survival. Our study delineates a novel host–parasite epigenetic interface, positioning T. annulata as a unique model of epigenetic parasitism. By bridging parasitology and cancer epigenetics, these findings unveil new therapeutic opportunities targeting chromatin vulnerabilities in parasite-induced transformation.

Drug Repurposing: A Fast-Track Strategy Against Protozoan Parasites

Confronting drug resistance and the high cost of new drug discovery, our lab is pioneering a systematic pipeline to identify existing clinical compounds for use against T. annulata and related parasites. By integrating high-content phenotypic screening with deep mechanistic validation, we rapidly pinpoint drugs that selectively target the infected cell while sparing healthy hosts.

Our pipeline has successfully identified three distinct classes of repurposed candidates:

• Artemisinin Derivatives (Artesunate & Dihydroartemisinin):Our foundational work showed these antimalarials selectively eradicate Theileria-transformed cells by triggering a cascade of ROS-mediated DNA damage, p53 activation, and apoptosis. Crucially, they act synergistically with the frontline drug buparvaquone, enhancing its efficacy.

   

• Ursolic Acid:This natural product proved effective against both sensitive and buparvaquone-resistant parasite lines. It acts through a multi-pronged mechanism, inducing mitochondrial dysfunction, cell-cycle arrest, and disrupting essential host-parasite survival pathways.

   

• Epigenetic Inhibitors:In our most recent advance, a targeted screen of a 148-compound epigenetic drug library revealed potent HDAC and sirtuin inhibitors. These compounds exhibit strong anti-theilerial activity, with in silico models predicting direct binding to parasite epigenetic regulators, opening a new front in this battle.

Through this iterative strategy, we are building a robust portfolio of next-generation therapeutic candidates, offering new hope for controlling bovine theileriosis and providing a blueprint for tackling other protozoan diseases.

Genomic Surveillance of Protozoan Parasites: Decoding Diversity for Better Control

Our lab leverages advanced genomics, including Whole Genome Sequencing (WGS), to map the evolving genetic landscape of T. annulata and other protozoan parasites. By conducting large-scale population genomic studies on clinical isolates across India, we have uncovered critical insights into the parasite’s evolution and spread.

• Key Genomic Findings from WGS and Population Analysis:
  High Diversity in Field Strains: Our WGS efforts have revealed substantial genetic complexity in natural T. annulata populations, characterized by high allelic diversity, heterozygosity, and significant antigenic variation. This diversity poses a challenge for sustained immunity and necessitates vigilant surveillance.
• Bottleneck in Vaccine Strains:
  In contrast, WGS-based comparisons identified limited genetic diversity and a low multiplicity of infection within vaccine lines. This discovery provides a clear genetic roadmap for refining and updating vaccine formulations to ensure broad and lasting protection.
• Translating Genomics into Precision Diagnostics:
  To bridge the gap between genomic data and field application, we have developed a suite of highly sensitive molecular tools:

1. A Quantitative Real-Time PCR Assay that directly measures the parasite-to-host DNA ratio in clinical samples, offering a precise metric for infection burden.
2. A Multiplex Digital Droplet PCR (ddPCR) Platform that provides absolute quantification of parasite load, significantly enhancing early detection, monitoring treatment response, and offering superior robustness compared to conventional PCR methods.

By integrating deep genomic surveillance via WGS with cutting-edge diagnostics, we are building a robust framework for the proactive and precise control of bovine theileriosis and related haemoparasites.

Combating Antimicrobial Resistance (AMR)

AMR is a critical One Health challenge, eroding the efficacy of treatments for bacterial infections in both animals and humans. In the livestock sector, AMR, particularly in mastitis-causing ESKAPE pathogens, leads to severe production losses and threatens food security.

Our lab is at the forefront of AMR research, employing an integrative strategy to decipher resistance mechanisms and pioneer novel countermeasures. Our approach is built on four key pillars:

• Genomic Surveillance:We conduct systematic surveillance to track the emergence and dissemination of resistant ESKAPE pathogens and AMR genes across livestock populations, providing critical data for containment strategies.
• Mechanistic Decoding:Using multi-omics technologies (genomics, transcriptomics, proteomics), we deconstruct the molecular mechanisms of resistance. This allows us to identify key regulatory networks and genetic vulnerabilities in resistant pathogens.
• Therapeutic Innovation:We develop new anti-infective strategies by repurposing existing drugs, designing potent synergistic combinations, and characterizing novel antimicrobial compounds from natural sources to bypass existing resistance pathways.
• Microbiome-Mediated Solutions:We explore the therapeutic potential of the gut microbiome, investigating how specific commensals and their bioactive metabolites can restore microbial balance, enhance animal health, and reduce reliance on traditional antibiotics.

Through this comprehensive research, we aim to generate the knowledge and tools needed to curb the spread of AMR, improve animal welfare, and ensure the sustainability of livestock production.

Genomic Surveillance of AMR pathogens to Point-of-Care Detection

Our lab has pioneered genomic surveillance strategies for Staphylococcus aureus, a major cause of bovine mastitis. Through a series of interconnected studies, we have moved from uncovering hidden AMR threats to developing rapid field-deployable diagnostics, establishing a comprehensive framework for managing this pathogen.

• Revealing a Hidden Threat: The OS-MRSA Enigma
  Our 2016 study in PLoS ONE was a sentinel discovery, reporting the emergence of oxacillin-susceptible mecA-positive (OS-MRSA) strains in bovine mastitis. This finding exposed a cryptic MRSA reservoir that evades routine phenotypic detection, underscoring the critical need for molecular surveillance to accurately assess the true burden of antimicrobial resistance.
• Mapping the Epidemic: Genotyping and AMR Determinants
  In our 2022 follow-up in Microorganisms, we deployed comprehensive genomic tools to map the landscape of clinical S. aureus in India. By integrating whole-genome sequencing, resistance gene profiling, and virulence factor analysis, we identified the dominant circulating sequence types and the specific genetic determinants driving AMR in mastitis, providing a crucial evidence base for targeted interventions.
• Translating Surveillance to the Field: A Rapid Diagnostic Sensor
  To bridge the gap between the lab and the farm, we engineered a novel solution. Our 2019 paper in Biosensors & Bioelectronics detailed a chemiresistive DNA-hybridization sensor for the direct genetic detection of S. aureus. This technology demonstrates the feasibility of rapid, point-of-care molecular diagnostics, bringing the power of genomic surveillance directly to the field for instant, informed decision-making.

• Commitment to a Genomic Framework

Collectively, this body of work underscores our lab’s dedication to building a modern genomic surveillance framework for livestock health, one that enhances detection accuracy, tracks the evolution of resistance in real-time, and ultimately empowers evidence-based strategies to safeguard bovine health and productivity.

Mechanistic Decoding of AMR Pathways

A core focus of our lab is to deconstruct the molecular mechanisms that major bacterial pathogens use to evade antimicrobials. We employ integrated genomics, transcriptomics, and phenotyping to unravel the complex resistance pathways in priority pathogens, providing a foundational knowledge for countering AMR.

The OS-MRSA Enigma: A Case Study in Cryptic Resistance

Our work on oxacillin-susceptible MRSA (OS-MRSA) exemplifies this approach, deciphering the unique biology of a cryptic pathogen that carries the mecA resistance gene yet tests as susceptible to antibiotics. We seek to understand how this “sleeper agent” evades detection and rapidly activates its resistance under therapeutic pressure.

Our findings reveal a sophisticated two-stage survival strategy:

Stage 1: The Trojan Horse

In its dormant state, OS-MRSA significantly downregulates the femXAB operon, a key complex for peptidoglycan cross-linking. This creates a compromised, weakened cell wall that is inherently vulnerable to β-lactam antibiotics, explaining its apparent susceptibility. Crucially, the mecA gene is present but functionally latent, allowing the bacterium to masquerade as a treatable infection.

Stage 2: Activation Under Fire

Upon exposure to oxacillin, OS-MRSA undergoes a dramatic adaptive shift. It activates key pathways, including altered expression of ltaS and sceD, which remodel the cell envelope. This response triggers a coordinated survival phenotype:

Physiological Changes: Reduced growth rate and increased cell size.

Resistance Emergence: A significant increase in the Minimum Inhibitory Concentration (MIC).

Stealth Retention: Critically, this induced resistance does not compromise virulence, allowing the pathogen to persist during infection and evade standard treatment regimens.

Impact: By exposing this molecular switch, we have redefined OS-MRSA as a high-threat, cryptic reservoir of resistance. This work provides the essential mechanistic foundation needed to develop next-generation diagnostics that can detect this latent threat and more effective therapeutic strategies to prevent its dangerous activation.

A One Health Strategy: Drug Repurposing at the Human-Animal Interface

The global fight against Antimicrobial Resistance (AMR) is uneven. Disparities in drug accessibility and regulatory frameworks between low- and middle-income countries (LMICs) and high-income countries (HICs) create hotspots for AMR emergence. In LMICs, factors like over-the-counter antibiotic availability and limited healthcare access often lead to unregulated use, while HICs operate under stricter stewardship. Our research tackles this complex challenge through a One Health lens, focusing on drug repurposing as a rapid, cost-effective strategy to discover new weapons against resistant pathogens like Staphylococcus aureus.

From Global Insight to Drug Discovery
We bridge the gap between AMR epidemiology and practical therapeutic solutions. By systematically screening compound libraries like the MMV Pathogen Box, we have identified several potent anti-staphylococcal leads, including:

MMV676501

MMV102872

MMV687807

MMV1804559

Our work goes beyond identification; we are actively deciphering their mechanisms of action, revealing how they disrupt key metabolic pathways and virulence systems in S. aureus.

Expanding the Arsenal: Beyond Conventional Compounds
In parallel, we are exploring novel chemical spaces. We have demonstrated that macrocyclic copper (II) complexes and other repurposed chemical scaffolds exhibit strong antibiofilm activity, presenting promising candidates for treating persistent, device-associated infections that are notoriously difficult to eradicate.

A Holistic Vision
By connecting the dots between global AMR drivers, systematic drug discovery, and mechanistic validation, our lab embodies a holistic approach. We are committed to developing accessible, next-generation therapeutic strategies that mitigate the threat of bacterial pathogens across human, animal, and environmental interfaces.

The Gut Microbiome: A New Front in the Fight against AMR

Our lab mines the bovine gut microbiome for novel antimicrobials while monitoring the impact of antibiotic treatments. Using an integrated multi-omics approach, we:

Discover New Therapeutics: Using 16S rRNA sequencing, proteomics, and metabolomics, we identify and characterize natural antimicrobial producers, uncovering novel bacteriophages, antimicrobial peptides, and metabolites.

Assess Antibiotic Impact: We simultaneously use these tools to understand how antibiotic exposure disrupts gut microbial balance and promotes resistance.

This dual-strategy positions the gut microbiome as a central pillar in developing sustainable anti-infective strategies and upholding One Health principles.

2025

• Dandasena, D., Suresh, A., Budhwar, R. et al. Genomic characterization of host gene alterations in Theileria annulata-transformed leukocytes. Commun Biol 8, 1622 (2025).
• Singh, S., Subudhi, M., Suresh, A., & Sharma, P. (2025). Ursolic acid induces apoptosis and disrupts host-parasite interactions in Theileria annulata-infected cells. International Journal for Parasitology: Drugs and Drug Resistance, 28, 100593.
• Dandasena, D., Suresh, A., Bhandari, V., Roy, S., & Sharma, P. (2025). Theileria annulata Hijacks Host Signaling: Integrated Phosphoproteomics and transcriptomics Unveils ERK1/2 as a Central Regulator of Host Transcription Factors. Molecular & Cellular Proteomics, 100992.
• Sharma, P., Thakur, S., Dandasena, D., Suresh, A., Subudhi, M., Kamble, S., … & Bhandari, V. (2025). Epigenetic Reprogramming of Host Chromatin by the Transforming Parasite Theileria annulata. bioRxiv, 2025-10.
• Bhandari, V., Brahma, U., Suresh, A., Kamila, A., S, U., SV, A. K., … & Sharma, P. (2025). Proteomic Insights into Strong and Weak Biofilm Formation in Acinetobacter baumannii for Potential Therapeutic Targets. bioRxiv, 2025-10.
• Brahma, U., Singothu, S., Suresh, A., Vemula, D., Munagalasetty, S., Sharma, P., & Bhandari, V. (2024). MMV 1804559 is a potential antistaphylococcal and antibiofilm agent targeting the clfA gene of Staphylococcus aureus. Journal of Applied Microbiology, 135(11), lxae276.

2024

• Kamble, S., Singh, S., Suresh, A., Singothu, S., Dandesena, D., Bhandari, V., & Sharma, P. (2024). Epidrugs: alternative chemotherapy targeting Theileria annulata schizont stage parasites. Microbiology Spectrum, 12(4), e03258-23.
• Dandesena, D., Suresh, A., Budhwar, R., Godwin, J., Singh, S., Subudhi, M., … & Sharma, P. (2024). Theileria annulata Infection Promotes p53 suppression, Genomic Instability and DNA deaminase APOBEC3H upregulation leading to cancer-like phenotype in host cells. bioRxiv, 2024-02.
• Suresh, A., Brahma, U., Bhandari, V., & Sharma, P. (2024). Unveiling the antimicrobial action of MMV676501, MMV687807, and MMV102872 against Staphylococcus aureus: A mechanistic investigation. Current Research in Biotechnology, 8, 100245.

2023

• Barman, M., Dandasena, D., Suresh, A., Bhandari, V., Kamble, S., Singh, S., … & Sharma, P. (2023). Artemisinin derivatives induce oxidative stress leading to DNA damage and caspase-mediated apoptosis in Theileria annulata-transformed cells. Cell Communication and Signaling, 21(1), 78.
• Murthy, S., Suresh, A., Dandasena, D., Singh, S., Subudhi, M., Bhandari, V., … & Sharma, P. (2023). Multiplex ddPCR: A promising diagnostic assay for early detection and drug monitoring in bovine theileriosis. Pathogens, 12(2), 296.

2022

• Brahma, U., Suresh, A., Murthy, S., Bhandari, V., & Sharma, P. (2022). Antibiotic resistance and molecular profiling of the clinical isolates of Staphylococcus aureus causing bovine mastitis from India. Microorganisms, 10(4), 833.

2021

• Barman, M., Kamble, S., Roy, S., Bhandari, V., Singothu, S., Dandasena, D., … & Sharma, P. (2021). Antitheilerial activity of the anticancer histone deacetylase inhibitors. Frontiers in Microbiology, 12, 759817.
• Roy, S., Bhandari, V., Barman, M., Kumar, P., Bhanot, V., Arora, J. S., … & Sharma, P. (2021). Population genetic analysis of the Theileria annulata parasites identified limited diversity and multiplicity of infection in the vaccine from India. Frontiers in microbiology, 11, 579929.

2019

• Paresh Sharma, Sonti Roy, Vasundhra Bhandari, Debabrata Dandasena, Shweta Murthy. Genetic profiling reveals high allelic diversity, heterozygosity and antigenic diversity in clinical isolates of Theileria annulata from India. Front Physiol. 2019; doi:10.3389/fphys.2019.00673.
• U Brahma, P Sharma, S Murthy, S Sharma, S Chakraborty, SN Appalaraju, V Bhandari. Decreased expression of femXAB genes and fnbp-mediated biofilm pathways in OS-MRSA clinical isolates. Sci Rep. 2019; 9(1):1–8.
• Tripathy S, Bhandari V, Sharma P, Vanjari SRK, Singh SG. Chemiresistive DNA hybridization sensor with electrospun nanofibers: A method to minimize inter-device variability. Biosens Bioelectron. 2019; 133:24–31.
• Vandna Bhanot, Anita Ganguly, Paresh Sharma. Hematological alterations and molecular detection of theileriosis in crossbred cattle. Indian J Anim Sci. 2019; 89(6):2100.

2018

• Dandasena D, Bhandari V, Sreenivasamurthy GS, Murthy S, Roy S, Bhanot V, Arora J, Singh S, Sharma P. A real-time PCR–based assay for determining parasite-to-host ratio and parasitemia in clinical samples of bovine theileriosis. Sci Rep. 2018.
• Brahma U, Kothari R, Sharma P, Bhandari V. Antimicrobial and anti-biofilm activity of hexadentated macrocyclic complex of copper(II) derived from thiosemicarbazide against Staphylococcus aureus. Sci Rep. 2018; 8(1):8050.
• Vasundhra Bhandari, Shalini Chakraborty, Umarani Brahma, Paresh Sharma. Identification of anti-staphylococcal and anti-biofilm compounds by repurposing the Medicines for Malaria Venture Pathogen Box. Front Cell Infect Microbiol. 2018; 8:365.

2017

• Chakraborty S, Roy S, Mistry H, George N, Murthy S, Bhandari V, Sharma P. Potential sabotage of host cell physiology by Apicomplexan parasites for survival benefits. Front Immunol. 2017; 8:1261.
• Mahato S, Mistry HU, Chakraborty S, Sharma P, Saravanan R, Bhandari V. Identification of variable traits among methicillin-resistant and -sensitive coagulase-negative staphylococci from mastitic cow milk samples in India. Front Microbiol. 2017; 8:1446.

2016

• N George, V Bhandari, P Sharma. Phylogenetic relationship and genotypic variability in Anaplasma marginale strains causing anaplasmosis in India. Infect Genet Evol. 2016.
• H Mistry*, P Sharma*, S Mahato, R Saravanan, PA Kumar, V Bhandari. Prevalence and characterization of oxacillin-susceptible mecA-positive clinical isolates of Staphylococcus aureus causing bovine mastitis in India. PLoS ONE. 2016; 11:e0162256.
• Sharma V, Sharma P, Selvapandiyan A, Salotra P. Leishmania donovani-specific Ub-related modifier-1: an early endosome-associated ubiquitin-like conjugation in Leishmania donovani. Mol Microbiol. 2016; 99(3):597–610.

2015

• N George, V Bhandari, DP Reddy, P Sharma. Emergence of new genotype and diversity of Theileria orientalis parasites from bovines in India. Infect Genet Evol. 2015; 36:27–34.
• George N, Bhandari V, Reddy DP, Sharma P. Molecular and phylogenetic analysis revealed new genotypes of Theileria annulata parasites from India. Parasitol Vectors. 2015; 8:468.
• Sharma P, Reddy DP, Kumar P, Gadicherla R, George N, Bhandari V. Draft genome of Staphylococcus aureus strain isolated from a clinical mastitis-infected cattle. Genome Announcements. 2015.
• Sharma P, Rayavara K, Ito D, Basore K, Desai SA. A CLAG3 mutation in an amphipathic transmembrane domain alters malaria parasite nutrient channels and confers leupeptin resistance. Infect Immun. 2015; 83(6):2566–2574.

Lab Members:
S. Akash | Senior Research Fellow
M.Sc. (Biotechnology), The Maharaja Sayajirao University of Baroda, Gujarat.
Research interest: Antimicrobial Resistance

Linkedin Profile: https://www.linkedin.com/in/akash-suresh-5816ba15b/

Sakshi Singh | Senior Research Fellow
M.Sc. (Genetics), Maharshi Dayanand University, Haryana.
Research interest: Host Pathogen Interaction

Linkedin Profile: https://www.linkedin.com/in/sakshi-singh-4152a9382/

Madhusmita Subudhi | Senior Research Fellow
M.Sc. (Life Science), NIT Rourkela, Orissa.
Research interest: Host Pathogen Interaction (Epigenetics)

Linkedin Profile: https://www.linkedin.com/in/madhusmita-subudhi-a3970413a/

Vengatachala Moorthy A | Senior Research Fellow
M.Sc. (Biochemistry), PSG Coimbatore, Tamil Nadu.
Research interest: Host Pathogen Interaction

Linkedin Profile: https://www.linkedin.com/in/vengatachala-moorthy-a-138b431a4/

Samoel Lareb | Project Associate- II
M.Sc. (Biomedical Sciences) University of Delhi
Research interest: Host Pathogen Interaction

Linkedin Profile: https://www.linkedin.com/in/samoel-lareb-51410b307/

Jaya Limbu | Junior Research Fellow
M.Sc. (Biotechnology), Mizoram University, Aizawl, Mizoram.
Research interest:  Host Pathogen Interaction (Epigenetics)

Lab Alumni:
Dr. Debabrata Dandasena | PhD Student

Sonam Kamble | PhD Student

Srimathi Rameshan | Project Associate

Amruthanjali | Project Associate

Umarani Brahma | Project Associate

Shweta Nori | DST-Inspire Young Women Scientist

Dr. Sonti Roy | PhD Student

Dr. Madhumani Barman | Project Associate

Dr. Vasundhra Bhandari | DST-Inspire Faculty

1. Identification of Virulence factors associated with Theileria annulata ( From DBT, India)

2. Genome-wide association study for identification of novel loci associated with resistance to Theileriosis in India. ( From DBT, India)

3. Virulence/disease pathogenesis during Bovine Mastitis ( From DBT, India)

4. Evaluation of Anti-inflammatory Natural Compounds for Therapeutic use in Mastitis of Dairy Animals. (From Ayush, India)

Room 204, 2nd Floor B Wing
National Institute of Animal Biotechnology
Survey No. 37, Opp. Journalist Colony
Extended Q City Road, Near Gowlidoddy
Gachibowli, Hyderabad
Telangana – 500032

Email: paresh[at]niab[dot]org[dot]in
Tel: +91-(0)40-2312-0144

 We welcome applications from enthusiastic candidates (JRFs/SRFs/ PDF/Trainees) who are interested in research at our lab. Candidates seeking a position can write to paresh@niab.org.in with a brief CV and one-page research statement explaining how you fit in our lab and why you want to join…